TriangleHEALTH PROFESSIONAL · SOURCE READING
Dasatinib
Source: Childhood Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 10, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Childhood CML / TKI Therapy
Dasatinib is a TKI that is approved by the U.S. Food and Drug Administration (FDA) for the treatment of children with CML.
Evidence (dasatinib in children):
A phase I trial of dasatinib in children showed that drug disposition, tolerability, and efficacy of this agent was similar to that observed in adults.[15,16]
A phase II trial of dasatinib, which included 84 children with newly diagnosed CML in chronic phase, used a dose of 60 mg/m2 (tablets) or 72 mg/m2 (oral solution) given to patients once daily.[2]
Source links and citations
A phase II trial of dasatinib, which included 84 children with newly diagnosed CML in chronic phase, used a dose of 60 mg/m2 (tablets) or 72 mg/m2 (oral solution) given to patients once daily.[2]
Complete cytogenetic response and MMR (≥3-log reduction or ≤0.1% on the International Scale [IS]) were achieved in 92% and 52% of patients, respectively, after 12 months of therapy.
A phase II trial of dasatinib, which included 84 children with newly diagnosed CML in chronic phase, used a dose of 60 mg/m2 (tablets) or 72 mg/m2 (oral solution) given to patients once daily.[2]
The 4-year PFS rate was 93%.
A phase II trial of dasatinib, which included 84 children with newly diagnosed CML in chronic phase, used a dose of 60 mg/m2 (tablets) or 72 mg/m2 (oral solution) given to patients once daily.[2]
Dasatinib was well tolerated, with very few grade 3 or grade 4 adverse events. No pleural or pericardial effusions or pulmonary complications were observed.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice